The identification of the TMPRSS2:ERG fusion as a frequent molecular alteration occurring in nearly half of prostate cancer cases has revolutionized our comprehension of the underlying mechanisms driving this malignancy. The gene discussed is TMPRSS2; the disease is prostate carcinoma.